- Home
- TLSI vs MNPR Comparison
TLSI vs MNPR Comparison
Compare TLSI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- MNPR
- Stock Information
- Founded
- TLSI 2010
- MNPR 2014
- Country
- TLSI United States
- MNPR United States
- Employees
- TLSI N/A
- MNPR N/A
- Industry
- TLSI Medical Specialities
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- MNPR Health Care
- Exchange
- TLSI Nasdaq
- MNPR Nasdaq
- Market Cap
- TLSI 124.9M
- MNPR 113.5M
- IPO Year
- TLSI N/A
- MNPR 2019
- Fundamental
- Price
- TLSI $3.95
- MNPR $30.26
- Analyst Decision
- TLSI Strong Buy
- MNPR Strong Buy
- Analyst Count
- TLSI 6
- MNPR 3
- Target Price
- TLSI $11.75
- MNPR $27.33
- AVG Volume (30 Days)
- TLSI 52.7K
- MNPR 93.6K
- Earning Date
- TLSI 11-14-2024
- MNPR 11-08-2024
- Dividend Yield
- TLSI N/A
- MNPR N/A
- EPS Growth
- TLSI N/A
- MNPR N/A
- EPS
- TLSI N/A
- MNPR N/A
- Revenue
- TLSI $26,891,000.00
- MNPR N/A
- Revenue This Year
- TLSI $60.97
- MNPR N/A
- Revenue Next Year
- TLSI $53.69
- MNPR N/A
- P/E Ratio
- TLSI N/A
- MNPR N/A
- Revenue Growth
- TLSI 67.90
- MNPR N/A
- 52 Week Low
- TLSI $3.50
- MNPR $1.55
- 52 Week High
- TLSI $10.42
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- TLSI 46.18
- MNPR 72.16
- Support Level
- TLSI $3.76
- MNPR $20.16
- Resistance Level
- TLSI $4.17
- MNPR $31.96
- Average True Range (ATR)
- TLSI 0.35
- MNPR 2.67
- MACD
- TLSI -0.04
- MNPR 0.48
- Stochastic Oscillator
- TLSI 33.66
- MNPR 80.48
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.